Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Biomarker Study: Impact of Single Doses of LY2979165 and LY2140023 on the Ketamine-Challenge Pharmacological MRI Assay in Healthy Male Subjects

NCT01524237 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01524237
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01524237 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Biomarker Study: Impact of Single Doses of LY2979165 and LY2140023 on the Ketamine-Challenge Pharmacological MRI Assay in Healthy Male Subjects
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2012
Completion date
July 31, 2013
Enrollment
52 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers